|
Diabetes Medication Article
FDA's Role in Regulating Insulin
FDA's Center for Drug Evaluation and Research (CDER) oversees drug products, including insulin. CDER makes sure that drugs sold in the U.S. are safe and effective. The center evaluates new types of insulin products, and it regulates the manufacturing, labeling, and advertising of insulin products.
Companies wanting to market insulin products are responsible for testing their products and submitting data showing they are safe and effective. At CDER, teams of doctors, statisticians, and scientists review new drug applications (NDAs). In some cases, FDA seeks help from advisory committees made up of outside experts.
Once a new insulin product is on the market, CDER monitors its quality and makes sure that its manufacturer follows FDA laws and regulations. CDER also monitors insulin products carefully after they are approved to identify any unexpected side effects. Through a system called MedWatch, health professionals and consumers can report serious adverse reactions to any medical product. CDER collects information from MedWatch and the drug industry and conducts statistical evaluations on drug usage, adverse reactions, poisonings, safety, and effectiveness. If necessary, CDER shares information with patients and health professionals.
Diabetes Testing Center
Heart News Center
Hot Home Gym Reviews
The Secret Wisdom You Have Inside
Get Rid of Your Belly fat
Diabetic Prescription News
Diabetic Prescription
IMPORTANT: Bing News RSS feed has moved!
After two delays, the Food and Drug Administration approved once-weekly injectable Bydureon for treating adults with Type 2 diabetes, which is linked to poor diet and lack of exercise. Bydureon is a longer-acting form of Amylin's older Byetta ...
Read moreU.S. FDA approves Amylin's diabetes drug
Amylin Pharmaceuticals Inc. (AMLN) and Alkermes Plc (ALKS) succeeded in their third attempt to gain U.S. clearance for Bydureon, a once-weekly version of Amylin’s diabetes shot. Bydureon is a long-acting form of Byetta, a twice-daily injection ...
Read moreAmylin, Alkermes Long-Acting Diabetes Drug Wins FDA Approval on Third Try
Alkermes Inc. (Nasdaq: ALKS) and its California partner Amylin Pharmaceuticals Inc. (Nasdaq: AMLN) have finally won approval from the FDA for the diabetes drug Bydureon after years of attempts. In a letter from the U.S. Food and Drug ...
Read moreAlkermes diabetes drug wins FDA approval
Jan. 19 (Bloomberg) -- Bristol-Myers Squibb Co. and AstraZeneca Plc failed to win U.S. clearance to sell the first in a new class of experimental diabetes pills as regulators sought more data on the medicine’s safety. The Food and Drug ...
Read moreBristol, AstraZeneca Diabetes Drug Fails to Win FDA Backing
Updates with stock prices, company comment. SAN DIEGO (TheStreet (Symbol : TST)) -- Amylin Pharmaceuticals (Symbol : AMLN) received U.S. approval Friday for its diabetes drug Bydureon, setting the stage for a commercial battle against an established rival ...
Read moreThird Time's The Charm for Approval of Amylin Diabetes Drug
The battle to treat diabetes has taken on a new level of challenge as evidence linking the popular drug Actos with an increased risk of bladder cancer continues to mount. The results of a preliminary study by the Food and Drug Administration (FDA) in June ...
Read moreEuropean Recalls of Diabetes Drug a Sign of Things to Come?
Celebrity chef Paula Deen announced last week that she has type 2 diabetes and she is getting paid to pitch a diabetes drug, but she’s also become the reluctant poster woman for what not to do to avert diabetes. News stations have been running ...
Read moreExtra pounds lead to type 2 diabetes
WASHINGTON (January 27, 2012)--Federal health regulators have approved Amylin Pharmaceutical's long-delayed diabetes drug Bydureon, a next-generation treatment that requires fewer injections than the company's current offering, Byetta. The U.S. Food and ...
Read moreLong-Delayed Diabetes Drug Wins Approval
Of the diagnosed patients, 16% are not being treated with drugs. We estimate that the adult type 2 diabetes drug-treated population in the seven major markets is close to 27 million patients. Physicians report 278 different class combinations used across ...
Read more